E. F. Smit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
E. F. Smit has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
P E Postmus
15 shared publicationsH H Berendsen
5 shared publications- Frank J. Lagerwaard
Department of Radiation Oncology, VU Medical Center, Amsterdam, The Netherlands
4 shared publications S. Senan
Dept of Radiation Oncology, Vrije University Medical Centre (VUMC), Amsterdam, Netherlands
4 shared publicationsB.J. Slotman
3 shared publicationsD T Sleijfer
3 shared publications
Latest Publications
- Open Access
- 16 March 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, i18
Outcome of Surgical Salvage for Local Failures Following Stereotactic Ablative Radiotherapy (SABR)
- 16 March 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, i18
Open AccessOutcome of Surgical Salvage for Local Failures Following Stereotactic Ablative Radiotherapy (SABR)
- 1 May 2013
- Published by Elsevier in Lung Cancer
- Vol. 80, S22
48O TREATMENT OF MULTIPLE PRIMARY LUNG CANCERS (MLPC) WITH STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)
- 1 May 2013
- Published by Elsevier in Lung Cancer
- Vol. 80, S22
48O TREATMENT OF MULTIPLE PRIMARY LUNG CANCERS (MLPC) WITH STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)
- 1 October 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81 (2) , S79-S80
Stereotactic Ablative Radiotherapy (SABR) in Potentially Operable Patients with Stage I Non-small Cell Lung Cancer
- 1 October 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81 (2) , S79-S80
Stereotactic Ablative Radiotherapy (SABR) in Potentially Operable Patients with Stage I Non-small Cell Lung Cancer
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , 3059
Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug delivery of 11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents.
3059 Background: Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in patients with advanced-stage NSCLC cancer. It has been hypothesized that pre-treatment with anti-angiogenic drugs may transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy (Nat Med 2001;7:987-9). The purpose of the present study was to investigate this concept in NSCLC patients using a perfusion tracer ([15O]H2O), radiolabeled chemotherapy ([11C]docetaxel) and positron emission tomography (PET) before and after a single infusion of bevacizumab. Methods: A total of 70 PET scans were scheduled in 10 NSCLC patients. Patients underwent dynamic PET scans with [15O]H2O and [11C]docetaxel before, and at 5 hours and 4 days after IV administration of bevacizumab (15 mg·kg-1). An additional [15O]H2O scan was performed at 2 hours. Systemic effects of bevacizumab were investigated by assessing: (1) plasma levels of vascular endothelial growth factor (VEGF) using ELISA kits, (2) blood pressure, (3) cardiac output using [15O]H2O, and (4) microcirculation in the skin using capillaroscopy. Results: Two hours after bevacizumab administration, tumor perfusion did not change (Wilcoxon Signed Ranks test , P = 0.89). At 5 hours, however, both tumor perfusion and the net influx rate constant of [11C]docetaxel decreased significantly (P < 0.05 for both). These changes persisted until day 4 (P < 0.01 for both). Changes in tumor parameters were accompanied by a rapid decrease in circulating VEGF at 3 hours (P < 0.05) and a decline in cardiac output at 4 days (P = 0.05). The other systemic parameters remained unchanged. Conclusions: A single dose of bevacizumab induces a rapid and significant decline in tumor perfusion and [11C]docetaxel delivery in NSCLC tumors. These rapid changes in tumor parameters are not due to changes in cardiovascular parameters. The findings of the present study highlight the importance of drug scheduling for enhancing drug delivery to tumors and advocate further studies to optimize scheduling of anti-angiogenic drugs.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , 3059
Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug delivery of 11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents.
3059 Background: Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in patients with advanced-stage NSCLC cancer. It has been hypothesized that pre-treatment with anti-angiogenic drugs may transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy (Nat Med 2001;7:987-9). The purpose of the present study was to investigate this concept in NSCLC patients using a perfusion tracer ([15O]H2O), radiolabeled chemotherapy ([11C]docetaxel) and positron emission tomography (PET) before and after a single infusion of bevacizumab. Methods: A total of 70 PET scans were scheduled in 10 NSCLC patients. Patients underwent dynamic PET scans with [15O]H2O and [11C]docetaxel before, and at 5 hours and 4 days after IV administration of bevacizumab (15 mg·kg-1). An additional [15O]H2O scan was performed at 2 hours. Systemic effects of bevacizumab were investigated by assessing: (1) plasma levels of vascular endothelial growth factor (VEGF) using ELISA kits, (2) blood pressure, (3) cardiac output using [15O]H2O, and (4) microcirculation in the skin using capillaroscopy. Results: Two hours after bevacizumab administration, tumor perfusion did not change (Wilcoxon Signed Ranks test , P = 0.89). At 5 hours, however, both tumor perfusion and the net influx rate constant of [11C]docetaxel decreased significantly (P < 0.05 for both). These changes persisted until day 4 (P < 0.01 for both). Changes in tumor parameters were accompanied by a rapid decrease in circulating VEGF at 3 hours (P < 0.05) and a decline in cardiac output at 4 days (P = 0.05). The other systemic parameters remained unchanged. Conclusions: A single dose of bevacizumab induces a rapid and significant decline in tumor perfusion and [11C]docetaxel delivery in NSCLC tumors. These rapid changes in tumor parameters are not due to changes in cardiovascular parameters. The findings of the present study highlight the importance of drug scheduling for enhancing drug delivery to tumors and advocate further studies to optimize scheduling of anti-angiogenic drugs.
- 1 July 2010
- Published by Elsevier in Annals of Oncology
- Vol. 22 (1) , 132-138
Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity
Background: Published trials of concurrent chemoradiotherapy (CCRT) in stage III non-small-cell lung cancer (NSCLC) generally excluded patients with significant comorbidity. We evaluated outcomes in patients who were selected by using radiation planning parameters and were considered, despite comorbidity, fit enough to receive cisplatin-based chemotherapy. Patients and methods: From 2003 to 2008, 89 patients with stage III NSCLC fit to receive cisplatin-based chemotherapy and a V20 Results: Median age was 64 years; performance status (PS) of zero, one or two in 20/64/5 patients; one or more comorbidities in 41.6%; 14% were treated previously for NSCLC. Median V20 was 26.6% (range 4%–39.4%). Grade III esophagitis and pneumonitis occurred in 28.1% and 7.9% of patients, respectively, while 4.5% died during treatment. Median overall survival was 18.2 months [95% confidence interval (CI) 13.1–23.3 months]. Independent prognostic factors for overall survival were PS (0 versus ≥1, P = 0.041) and planning target volume (P = 0.022). Conclusions: Patients with significant comorbidity who are fit to undergo cisplatin-based CCRT achieve median survivals similar to that reported in phase III trials and with relatively few late toxic effects.
- 1 July 2010
- Published by Elsevier in Annals of Oncology
- Vol. 22 (1) , 132-138
Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity
Background: Published trials of concurrent chemoradiotherapy (CCRT) in stage III non-small-cell lung cancer (NSCLC) generally excluded patients with significant comorbidity. We evaluated outcomes in patients who were selected by using radiation planning parameters and were considered, despite comorbidity, fit enough to receive cisplatin-based chemotherapy. Patients and methods: From 2003 to 2008, 89 patients with stage III NSCLC fit to receive cisplatin-based chemotherapy and a V20 Results: Median age was 64 years; performance status (PS) of zero, one or two in 20/64/5 patients; one or more comorbidities in 41.6%; 14% were treated previously for NSCLC. Median V20 was 26.6% (range 4%–39.4%). Grade III esophagitis and pneumonitis occurred in 28.1% and 7.9% of patients, respectively, while 4.5% died during treatment. Median overall survival was 18.2 months [95% confidence interval (CI) 13.1–23.3 months]. Independent prognostic factors for overall survival were PS (0 versus ≥1, P = 0.041) and planning target volume (P = 0.022). Conclusions: Patients with significant comorbidity who are fit to undergo cisplatin-based CCRT achieve median survivals similar to that reported in phase III trials and with relatively few late toxic effects.
- 1 March 2002
- Vol. 60 (1) , 17-21
Failure patterns of combined modality treatment in lung cancer: the impact of staging.
Patients with locally advanced non-small cell lung cancer (NSCLC) may be treated with induction chemotherapy (IC) followed by surgery with curative intent. The impact of staging inaccuracies on the failure rate of this intensive combined modality treatment approach, i.e. non-curative chemotherapy and thoracotomy, requires further investigation. The records of a cohort of 38 consecutive NSCLC IIIA-N2 patients treated with IC followed by surgery were reviewed. The clinical course strongly suggested that the standard diagnostic algorithm failed to demonstrate stage IV disease in 34% of the cases. Surgery instigated by CT-based response criteria at restaging after chemotherapy proved to be irradical in 70% of cases. Our data confirm the limitations of the current work-up of patients with apparently locally advanced NSCLC. This applies to the selection of patients to be assigned to combined modality treatment as well as to the post-chemotherapy assessment of resectability. Improved (re)staging of these patients will enhance the efficiency of intervention trials and prevent patients from being exposed to intensive and toxic therapy from which they derive no benefit.
- 1 March 2002
- Vol. 60 (1) , 17-21
Failure patterns of combined modality treatment in lung cancer: the impact of staging.
Patients with locally advanced non-small cell lung cancer (NSCLC) may be treated with induction chemotherapy (IC) followed by surgery with curative intent. The impact of staging inaccuracies on the failure rate of this intensive combined modality treatment approach, i.e. non-curative chemotherapy and thoracotomy, requires further investigation. The records of a cohort of 38 consecutive NSCLC IIIA-N2 patients treated with IC followed by surgery were reviewed. The clinical course strongly suggested that the standard diagnostic algorithm failed to demonstrate stage IV disease in 34% of the cases. Surgery instigated by CT-based response criteria at restaging after chemotherapy proved to be irradical in 70% of cases. Our data confirm the limitations of the current work-up of patients with apparently locally advanced NSCLC. This applies to the selection of patients to be assigned to combined modality treatment as well as to the post-chemotherapy assessment of resectability. Improved (re)staging of these patients will enhance the efficiency of intervention trials and prevent patients from being exposed to intensive and toxic therapy from which they derive no benefit.
- 1 August 2001
- Published by Elsevier in Lung Cancer
- Vol. 33 (2-3) , 267-275
Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling
- 1 August 2001
- Published by Elsevier in Lung Cancer
- Vol. 33 (2-3) , 267-275
Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling
- 29 December 2000
- Vol. 20, 3549-54
Validation of a polymerase chain reaction aided transcript titration assay (PATTY) for topoisomerase II in lung cancer samples.
This report describes the validation of a polymerase chain reaction aided transcript titration assay (PATTY) for tumor samples. The results obtained with the PATTY were compared to those of RNase protection in a set of 7 human lung cancer cell lines and in 23 non-small cell lung cancer samples derived from resected patients. Whereas between PATTY and RNase protection assay a good correlation was observed in the cell lines (r = 0.74, p = 0.057), no correlation was observed within the tumor samples (r = 0.06, p = 0.78). This was also the case when only tumors with a high percentage of tumor cells (> 90%) were selected. Although PATTY is a valuable tool to measure mRNA expression in cell lines, our results caution the use of PATTY in human tumor samples without proper validation. The possible causes of these results are discussed.
- 29 December 2000
- Vol. 20, 3549-54
Validation of a polymerase chain reaction aided transcript titration assay (PATTY) for topoisomerase II in lung cancer samples.
This report describes the validation of a polymerase chain reaction aided transcript titration assay (PATTY) for tumor samples. The results obtained with the PATTY were compared to those of RNase protection in a set of 7 human lung cancer cell lines and in 23 non-small cell lung cancer samples derived from resected patients. Whereas between PATTY and RNase protection assay a good correlation was observed in the cell lines (r = 0.74, p = 0.057), no correlation was observed within the tumor samples (r = 0.06, p = 0.78). This was also the case when only tumors with a high percentage of tumor cells (> 90%) were selected. Although PATTY is a valuable tool to measure mRNA expression in cell lines, our results caution the use of PATTY in human tumor samples without proper validation. The possible causes of these results are discussed.